Clinical development of lactocepin: A novel bacterial biologic?

Expert Review of Clinical Immunology

Volumn 8, Issue 7, 2012, Pages 597-599

  Van Huynegem, Karolien ^a   Steidler, Lothar ^a  

^a ActoGeniX NV   (Belgium)

Author keywords

chemokine; inflammatory bowel disease; lactocepin; Lactococcus lactis; probiotics

Indexed keywords

CORTICOSTEROID; LACTOCEPIN; MESALAZINE; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CHEESEMAKING; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG MECHANISM; EDITORIAL; ENTERITIS; FAECALIBACTERIUM PRAUSNITZII; GOOD LABORATORY PRACTICE; HUMAN; LACTOBACILLUS CASEI; LACTOBACILLUS PARACASEI; LACTOCOCCUS LACTIS; NONHUMAN; STAPHYLOCOCCUS AUREUS; ULCERATIVE COLITIS; YERSINIA ENTEROCOLITICA;

BIOLOGICAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; LACTOCOCCUS LACTIS; PROBIOTICS; SERINE ENDOPEPTIDASES;

EID: 84867773545     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.55     Document Type: Editorial

References (17)

1. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411(6837), 599-603 (2001). (Pubitemid 32531408)
2. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38(3), 365-375 (1996). (Pubitemid 26074316)
3. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 449(7164), 804-810 (2007). (Pubitemid 47598620)
4. Qin J, Li R, Raes J et al.; MetaHIT Consortium. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464(7285), 59-65 (2010).
5. Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc. Natl Acad. Sci. U.S.A. 109(2), 594-599 (2012).
6. Manichanh C, Reeder J, Gibert P et al. Reshaping the gut microbiome with bacterial transplantation and antibiotic intake. Genome Res. 20(10), 1411-1419 (2010).
7. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: A systematic review of intervention studies in adult patients. Drugs 72(6), 803-823 (2012).
8. Foligne B, Dessein R, Marceau M et al. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology 133(3), 862-874 (2007). (Pubitemid 47374132)
9. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an antiinflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl Acad. Sci. U.S.A. 105(43), 16731-16736 (2008).
10. von Schillde MA, Hörmannsperger G, Weiher M et al. Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. Cell Host Microbe 11(4), 387-396 (2012).
11. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology 119(2), 305-309 (2000). (Pubitemid 30621980)
12. Habimana O, Le Goff C, Juillard V et al. Positive role of cell wall anchored proteinase PrtP in adhesion of lactococci. BMC Microbiol. 7 36 (2007).
13. Buist G, Venema G, Kok J. Autolysis of Lactococcus lactis is influenced by proteolysis. J. Bacteriol. 180(22), 5947-5953 (1998). (Pubitemid 28514212)
14. Hoermannsperger G, Hörmannsperger G, Clavel T et al. Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation. PLoS ONE 4(2), e4365 (2009).
15. Steidler L, Hans W, Schotte L et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289(5483), 1352-1355 (2000). (Pubitemid 30656052)
16. Braat H, Rottiers P, Hommes DW et al. A Phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4(6), 754-759 (2006). (Pubitemid 43841860)
17. Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor α therapies. BioDrugs 24 (Suppl. 1), 3-14 (2010).